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Introduction
Staphylococcus aureus causes skin and soft-tissue
infections (SSTIs) that range from folliculitis to life-
threatening conditions, such as necrotizing fasciitis.1
Emerging methicillin resistance among Staphylococcus
aureus initially in nosocomial and recently in community
isolates is problematic because empirical choice of
antimicrobials must include agents with activity against
resistant strains.2 Management of MRSA infections is
challenging as these strains are resistant to all beta lactam
antibiotics. In contrast to health care associated MRSA
isolates that are resistant to multiple antibiotics, community-
associated MRSA isolates tend to be resistant to fewer
antibiotics and often remain susceptible to non-beta lactam
antibiotics, such as clindamycin, sulfonamides, and
tetracyclines.1,2
Vancomycin has excellent efficacy in skin and soft-
tissue infections in general and specifically against those due
to MRSA.3 However, for various reasons these agents should
be reserved for patients who have severe infections requiring
hospitalization or who have not responded to attempts to
eradicate the infection. Firstly, excessive use of vancomycin
would result in emergence of vancomycin resistance.2,3
Secondly, vancomycin is expensive and available only in
parenteral form and most of the times its administration
requires hospitalization.3 Finally, it is a nephrotoxic drug and
requires monitoring of renal function and drug levels that lead
to increased morbidity and costs for the patient.
Alternate options for the MRSA infections include
newer agents like linezolid, daptomycin, tigecycline, and
quinupristin/dalfopristin.3 However, these agents are either
very expensive or not available in Pakistan.3 Guidelines for
the treatment of skin and soft tissue infections published by
CDC in 2005 have also recommended the use of macrolides,
clindamycin, trimethoprim-sulfamethoxazole, tetracycline,
doxycycline or minocycline in minor MRSA infections.4
In addition, many studies from different regions of
the world have reported efficacy of fusidic acid, rifampicin,
clindamycin, tetracycline, cotrimoxazole and
chloramphenicol in skin and soft tissue infections with
MRSA.5,6 All of these antibiotics are potent
antistaphylococcal agents with good tissue penetration,
cheaper as compared to glycopeptides and are also available
in both oral and parenteral formulations.4 However, their use
is limited in developed countries due to their potential
adverse effects.
There is a strong need in resource limited countries
like Pakistan to review the utility of conventional antibiotics
effective for the management of skin and soft tissue infections
caused by MRSA. However, published data in Pakistan is
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Abstract
Objectives: To evaluate resistance rates in methicillin resistant Staphylococcus aureus (MRSA) against
clindamycin, cotrimoxazole, tetracycline, fusidic acid, rifampicin and chloramphenicol isolated from skin and soft
tissue infections (SSTI).
Methods: Descriptive analysis of SSTI samples yielding MRSA in clinical laboratory of a tertiary care center;
receiving specimens across Pakistan from January 2005 to June 2007.
Microbiological Methods: MRSA were identified using standard microbiological techniques. Susceptibility
testing was performed by disc diffusion according to Clinical Laboratory Standards Institute (CLSI) against fusidic
acid, tetracycline, cotrimoxazole, clindamycin, rifampicin and chloramphenicol. Minimum inhibitory
concentrations (MIC) of rifampicin were determined using agar dilution method according to CLSI. 
Results: During the study period 501 MRSA were isolated from SSTI. Overall variable susceptibility pattern with
high resistance rates to tetracycline (82%), clindamycin (79%), cotrimoxazole (59%), and rifampicin (50%) were
observed. Resistance to chloramphenicol (10%) and fusidic acid (9%) was low. 
Conclusion: There is a strong need in resource limited countries to review the utility of conventional antibiotics
for the management of MRSA SSTI as new agents are expensive and not available. High resistance rates were
observed against cotrimoxazole, tetracycline and clindamycin. Resistance to fusidic acid, rifampicin and
Chloramphenicol was low (JPMA 59:266; 2009).
limited in this regard. Therefore, this study was conducted to
explore the cheaper and easy to administer drugs for soft tissue
infections by MRSA. The susceptibility pattern of MRSA
strains were evaluated against fusidic acid, cotrimoxazole,
rifampicin, chloramphenicol, clindamycin and tetracycline
isolated from SSTIs. Moreover, studies from Pakistan that
reported susceptibility pattern of MRSA were reviewed and
their findings were correlated with our results. 
Material and Methods
This study was conducted at the Clinical Microbiology
Laboratory of Aga Khan University Hospital that receives
specimens from across Pakistan via its collection points. Skin
and soft tissue samples yielding growth of S.aureus from
January 2005 to June 2007 were included. Organisms were
identified as S.aureus by Gram stain, catalase and coagulase
test.7 Other supplemental tests were DNAse, phosphatase and
mannitol fermentation.7 Antimicrobial sensitivities against
oxacillin (1 g), fusidic acid (10 g), cotrimoxazole (30µg),
tetracycline (30µg), clindamycin (2µg) and chloramphenicol
(25 µg) were performed by Kirby Bauer method according to
Clinical Laboratory Standards Institute (CLSI).8 Methicillin
resistance was confirmed by oxacillin screen agar containing
6 g/ml oxacillin and incubation at 30 C for 24 hours.8
Sensitivities against rifampicin were determined by minimum
inhibitory concentration (MIC) method using agar dilution
according to CLSI.8
Literature review was done using Pubmed, google,
medscape and Pakmedinet using different terms "MRSA and
susceptibility pattern", "MRSA and skin and soft tissue" etc.
All the information was recorded on a standard questionnaire. 
Results
During the study period a total of 501 MRSA strains
were isolated from skin and soft tissue specimens. Overall,
variable susceptibility pattern was observed in MRSA
strains, with high resistance rates to tetracycline (TE)
(82%), clindamycin (DA) (79%), cotrimoxazole (SXT)
(59%), and rifampicin (R) (50%). Resistance to
chloramphenicol (C) (10%) and fusidic acid (FA) (9%) was
low (Figure). 
Analysis of data from the studies done in various
regions of Pakistan is shown in Table.
Discussion
Increasing antimicrobial resistance has emerged
globally as one of the paramount microbial threats of the
21st century.9 Infections due to MRSA are the significant
cause of morbidity and mortality worldwide. Incidence of
MRSA is increasing worldwide, and is escalating in
Pakistan.10-13 Previously MRSA infections were a concern
only in hospitals but now MRSA is isolated frequently from
the infections acquired in the community.14 Skin and soft
tissue infections are the major manifestations of
community-acquired MRSA strains. During the past 15
years emergence and dissemination of these strains had led
to major therapeutic and infection control related problems.
Methicillin resistance in Staphylococcus aureus
restricts therapeutic options for clinical isolates; especially
those isolated from SSTIs. Alternative treatment options
include fusidic acid, cotrimoxazole, clindamycin,
tetracycline, rifampicin, quinolones, and chloramphenicol.
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(FD= Fusidic acid, 10µg; C=Chloramphenicol, 25µg; R=Rifampicin; TE= Tetracycline,
30µg; SXT= Cotrimoxazole, 30µg; DA= Clindamycin, 2µg) 
Figure: Resistance pattern of MRSA.
Table: Percentage resistance in MRSA isolates reported in various studies from Pakistan.
Setting No. of MRSA Isolates TE C DA SXT FD RIF Reference
Lahore
2003-2005 307 100 - 37 96 - 5 J Hosp Infect23
Rawalpindi
2003 516 51 - 70 57 - 60 Emerg Infect Dis24
Rawalpindi
2001-2004 185 89 38 - 77 - - Pak J Med Sci10
Karachi
2004-2005 82 - - 90 - 2 - J Pak Med Assoc25
Karachi
2005-2007 501 82 10 79 59 9 50 Current study
Prediction of sensitivity to these drugs requires knowledge
of antibiotic susceptibility pattern of MRSA from a
particular region. Our MRSA strains from both hospital and
community showed low resistance to fusidic acid that is
comparable with studies reported from USA,9,14 Australia5
and South Africa.15 Fusidic acid is available in intravenous,
oral, and topical preparations and when given systemically
is widely distributed throughout the body, including areas
such as bone, joint fluid, prostate and large abscesses.16
Therefore, it can be particularly useful in treating MRSA.16
However, it is well recognized that use of fusidic acid, as
monotherapy, is associated with increased resistance as
compared to combination therapy.16 Therefore, combination
treatment with rifampicin or cotrimoxazole is advisable and
proven to be beneficial in treatment and eradication of
MRSA stains.5,9 Recent studies from different parts of the
world indicate increase in the usage of fusidic acid as
topical monotherapy for the treatment of skin infections
especially in Europe.17 Such topical therapy has proven
effective but has also been associated with significant
emergence of resistance.17 Thus, clinicians should
reconsider the use of topical fusidic acid monotherapy
especially for prolonged periods.
The resistance to rifampicin (50%) was relatively
better as compared to other agents. Rifampicin is another
oral antimicrobial agent with good tissue penetration. This
agent could be used to treat MRSA infections in our setting.
However, as Pakistan is a high burden Mycobacterium
tuberculosis (TB) country, increased usage of rifampicin is
not advisable as a routine for the management of MRSA
SSTI because of potential development of resistance in TB.
However, its use is justified in certain difficult clinical
situations when treatment options are very limited.
We observed high resistance rates to clindamycin,
tetracycline and cotrimoxazole in our MRSA isolates. A
higher rate of clindamycin resistance in endemic isolates is
disappointing as this drug has a very good efficacy in
MRSA SSTI.18
Cotrimoxazole has also been used in clinical studies
with a cure rate of 86-90% in MRSA SSTI18 Likewise,
tetracycline derivatives, doxycycline and minocycline also
have excellent tissue penetration, and demonstrate good
antistaphylococcal activity at clinically achievable levels
with a reported cure rate of 83% in MRSA skin and soft
tissue infections.19 However, high resistance rates to this
drug were observed in our study probably due to irrational
use of this antibiotic by general practitioners in Pakistan.
Another concern is the toxicity that is associated with
cotrimoxazole. 
Resistance to chloramphenicol was low (10%);
however, its role in management of MRSA soft tissue
infection is yet to be defined. There are certain trials of
usage of chloramphenicol in multi-drug resistant gram-
positive organisms like MRSA, vancomycin-intermediate
Staphylococcal.aureus (VISA), vancomycin-resistant
Staphylococcal.aureus (VRSA) and vancomycin-resistant
enterococcus (VRE).20 Chloramphenicol is routinely used
for the management of VRE infections at our institute. Data
for use of this antibiotic for the management of MRSA
infections is limited; however, it should be reserved for
cases when there are very limited therapeutic options.
Further clinical trials are needed before its routine use is
indicated for the treatment of MRSA infections.
In this study, all the strains showed susceptibility to
vancomycin. Vancomycin is a glycopeptide and is currently
a drug of choice for MRSA infections.4 Since there is
recognition of VRE, the emergence of VRSA has been
anticipated in future. There are few reports of VRSA/VISA
cases from US.21 One of the common risk factor for
acquiring VISA is the long-term use of vancomycin.22 It is
therefore important to consider alternate treatment options
for MRSA infections to prevent the VISA/VRSA
acquisition. The emergence of S.aureus with reduced
susceptibility to Vancomycin presents the potential for
infection with a virulent organism for which therapeutic
options are severely limited.
Comparison of our study results with other
published studies of Pakistan from Lahore,23 Rawalpindi24
and Karachi25 revealed resistance rates against clindamycin,
tetracycline and cotrimoxazole similar to our study.
Likewise, rifampicin sensitivity results and fusidate
sensitivity from a previous study done in Karachi25
correlated with our findings.
Conclusion
MRSA is a major pathogen in skin and soft tissue
infections worldwide. One of the limitations of this study is
the lack of differentiation between hospital acquired and
community associated strains. Therefore, no comments can
be made on the difference in susceptibility pattern of
community and hospital acquired strains. High resistance
rates against cotrimoxazole, tetracycline and clindamycin
were observed. Therefore, empirical therapy with these
agents at our centre is not recommended; however, these
agents could be used after the sensitivity results are
available. Resistance to fusidic acid and rifampicin was
low; however, as monotherapy with these agents could lead
to resistance, therefore, combination therapy should always
be used. Resistance to chloramphenicol was very low but
clinical trials recommending its use in MRSA skin and soft
tissue infections are limited and further evidence is required
before its routine use. 
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